AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, marking the latest drugmaker to commit to American manufacturing as looming tariffs threaten to raise costs across the industry.
The biopharmaceutical company said Monday that the investment includes plans for a new manufacturing center focused on chronic diseases. The multibillion-dollar facility would support the company’s weight-management and metabolic portfolio, including oral GLP-1s.